MacroGenics Inc. Shares Plummet Over 50% After Adverse Events in Vobra Duo Study Trend Down
New York, NY – MacroGenics Inc. (NASDAQ: MGNX) faced a significant drop in shares following the release of interim data from the TAMARACK Phase 2 study on their drug targeting B7-H3, an antigen present in various solid tumors. The study, focusing on previously treated patients with metastatic castration-resistant prostate cancer (mCRPC), revealed alarming results that led to a plunge of over 50% in the company’s stock value. The data, as of April 12, 2024, showed …